GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuron Ltd (FRA:ANW) » Definitions » Total Liabilities

Immuron (FRA:ANW) Total Liabilities : €1.45 Mil (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Immuron Total Liabilities?

Immuron's Total Liabilities for the quarter that ended in Dec. 2023 was €1.45 Mil.

Immuron's quarterly Total Liabilities increased from Dec. 2022 (€1.17 Mil) to Jun. 2023 (€1.47 Mil) but then declined from Jun. 2023 (€1.47 Mil) to Dec. 2023 (€1.45 Mil).

Immuron's annual Total Liabilities increased from Jun. 2021 (€0.74 Mil) to Jun. 2022 (€1.12 Mil) and increased from Jun. 2022 (€1.12 Mil) to Jun. 2023 (€1.47 Mil).


Immuron Total Liabilities Historical Data

The historical data trend for Immuron's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immuron Total Liabilities Chart

Immuron Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only 0.74 0.34 0.74 1.12 1.47

Immuron Semi-Annual Data
Jun15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.76 1.12 1.17 1.47 1.45

Immuron Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Immuron's Total Liabilities for the fiscal year that ended in Jun. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.375+(0.093+8.4134088584875E-17
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0.001)
=1.47

Total Liabilities=Total Assets (A: Jun. 2023 )-Total Equity (A: Jun. 2023 )
=13.621-12.152
=1.47

Immuron's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.365+(0+0.08
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0.001)
=1.45

Total Liabilities=Total Assets (Q: Dec. 2023 )-Total Equity (Q: Dec. 2023 )
=12.204-10.758
=1.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Immuron Total Liabilities Related Terms

Thank you for viewing the detailed overview of Immuron's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Immuron (FRA:ANW) Business Description

Traded in Other Exchanges
Address
Chapman Street, Unit 10, 25-37, Blackburn North, Melbourne, VIC, AUS, 3130
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

Immuron (FRA:ANW) Headlines

No Headlines